Inhibrx Reports Strong Phase 2 Data for INBRX-106 in HNSCC, Plans Phase 3 & NSCLC Expansion
INBX has more than doubled off its 52-week low of $10.84 on elevated volume (3.9× avg).
Summary
Inhibrx Biosciences announced highly positive interim Phase 2 results for INBRX-106 in Head and Neck Squamous Cell Carcinoma, showing a significant increase in objective response rate and complete responses, with plans to advance to Phase 3 and expand into other indications.
Key Events · Product Development and Regulatory · INBX
-
Positive Phase 2 HNSCC Data
INBRX-106 in combination with pembrolizumab achieved a 44.0% confirmed objective response rate (cORR) in first-line Head and Neck Squamous Cell Carcinoma (HNSCC), compared to 21.4% for pembrolizumab alone, representing a 22.6% absolute increase.
-
Complete Responses Observed
Three complete radiographic responses were observed in the INBRX-106 combination arm, while no complete responses were seen with pembrolizumab monotherapy.
-
Mechanistic Validation
Pharmacodynamic data supported the clinical findings, showing up to a 15-fold increase in T-cell proliferation and up to a four-fold increase in activation in combination-treated patients, consistent with INBRX-106's mechanism of action as a potent T-cell costimulator.
-
Advancing to Phase 3
The company plans to initiate the Phase 3 portion of the HexAgon study in Q3 2026, with progression-free survival data from Phase 2 expected in Q4 2026.
Analysis · INBX · Life Sciences
This filing details compelling interim Phase 2 data for INBRX-106, demonstrating a substantial improvement in confirmed objective response rates and complete responses in first-line HNSCC when combined with pembrolizumab. These results validate the drug's mechanism of action and support its potential to enhance checkpoint inhibitor efficacy across multiple large indications, including non-small cell lung cancer, representing a significant expansion of the company's pipeline opportunity. The planned initiation of a Phase 3 study and further clinical development in other settings will be key milestones to watch.
At the time of this filing, INBX was trading at $130.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $10.84 to $155.29. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.